IKZF1 and Miyoshi myopathy: According to the preclinical studies, CC-220 combined with bortezomib induced deep IKZF1 and IKZF3 degradation at clinically relevant concentrations and showed synergistically antiproliferative effects in MM cell lines, which could be further enhanced by dexamethasone.